Rising Demand for Asia-Pacific Cancer Biomarker Market Key Players, Growth Analysis during 2019-2025
Asia-Pacific cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. APAC is both a strong and promising market for biomarkers. This is particularly due to the strong population base, high prevalence of cancer in Asian countries such as China, Japan. Half of the global incidence of cancer is projected to occur in Asia with 22% in China and 7% in India alone. Biomarker development and adoption in these Asian countries will reduce the economic burden of cancer on the respective governments by timely and efficient diagnosis of diseases.
To Request a Sample of our Report on Asia-Pacific
Cancer Biomarker Market: https://www.omrglobal.com/request-sample/asia-pacific-cancer-biomarker-market
Changing lifestyles, increasing
urbanization, changes in reproductive patterns and diet, obesity, tobacco use,
alcohol drinking, chronic infection and increasing lifespans contribute to an
ever-increasing cancer burden and changing cancer pattern in Asian countries.
The projected increase will be largest in low-resource and medium-resource
countries in Asia. The cancer biomarker market has huge opportunities in APAC
due to increase in cancer cases, increase in R&D and growing medical
tourism. China is the second largest economy after the US and China has the
world’s largest population (1.4 billion), followed by India (1.3 billion). Both
China and India hold 40% of total world population share. As population of
India and China grows, its expanding share of older adults is particularly
notable.
The United Nations Population
Division projects that in India’s population with age 50 years and older will
reach 34% by 2050. Between 2010 and 2050, the share of 65 and older is expected
to increase from 5% to 14%, while the share in the oldest age group (80 and
older) will triple from 1% to 3%. Furthermore, Chinese authorities are
projecting the country's aged population (above 60 years old) will reach 255
million by 2020. The country’s ageing population will grow at an average rate
of 6.4 million a year. By 2020, there will be 255 million elders, representing
at least 17.8% of the entire Chinese population. With the age dynamics, cancer
cases in Asia Pacific are expected to grow.
(Get 15% Discount on Buying this Report)
A
full Report of Asia-Pacific Cancer Biomarker Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-cancer-biomarker-market
Asia-Pacific Cancer Biomarker Market Segmentation
By Biomarker Type
·
Genetic Biomarker
·
Protein Biomarker
By Cancer Type
·
Lung Cancer
·
Prostate Cancer
·
Breast Cancer
·
Colorectal Cancer
·
Cervical Cancer
·
Other
By Applications
·
Drug Discovery and Development
·
Diagnosis
·
Risk Assessment
·
Prognostics
By Profiling Technology
·
Omics Technology
·
Immunoassays
·
Cytogenetics
·
Bioinformatics
Regional Analysis
·
China
·
India
·
Japan
Rest of Asia-Pacific
Company Profiles
·
Abbott laboratories Inc.
·
Astellas Pharma Inc.
·
Becton, Dickson and Co.
·
Bio-Rad Laboratories, Inc.
·
Danaher Corp.
·
F. Hoffmann-La Roche Ltd.
·
Merck and Co., Inc.
·
Novartis AG
·
Pfizer Inc.
·
QIAGEN GmbH
·
Thermo Fisher Scientific Inc.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment